注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
ABVC Biopharma Inc是一家專注於植物來源的藥物和醫療器械開發的生物技術公司。該公司通過跟踪亞太地區研究機構的醫學發現或醫療器械技術來開發產品線。其在研產品包括ABV-1501、ABV-1504、ABV-1505、ABV-1703、ABV-1601、ABV-1701和ABV-2002。ABV-1504是一種植物性再攝取抑製劑,靶向去甲腎上腺素治療重度抑鬱症 (MDD)。該公司正在開髮用於治療注意力缺陷多動障礙(ADHD)的ABV-1505。該公司開發了用於治療癌症患者抑鬱症的ABV-1601。ABV-1501是三陰性乳腺癌 (TNBC) 的聯合療法。ABV-1701是玻璃體切除術的玻璃體替代品。ABV-1703是一種用於晚期不可手術或轉移性胰腺癌的藥物。ABV-2002是一種角膜儲存介質,由一種特殊的聚合物組成,用於保護眼組織免受滲透壓影響。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Eugene Jiang | 37 | 2015 | Chairman & Chief Business Officer |
Norimi Sakamoto | 53 | 2017 | Independent Director |
Yen-Hsin Chou | 35 | 2017 | Independent Director |
Susanna Cunningham-Rundles | - | - | Member of Scientific Advisory Board |
Yoshinobu Odaira | 74 | 2019 | Independent Director |
Tsang Ming Jiang | 63 | 2017 | Director |
Chang-Jen Jiang | 67 | 2017 | Director |
Keith McBurnett | - | 2023 | Member of Scientific Advisory Board |
Thomas P. Laughren | - | 2023 | Member of Scientific Advisory Board |
Yu-Min Chung | 58 | 2022 | Independent Director |
Shuling Jiang | 67 | 2022 | Director |
Hsin-Hui Miao | 55 | 2022 | Independent Director |
Yih-Shiou Hwang | - | 2023 | Member of Scientific Advisory Board |
Maurizio Fava | - | 2023 | Member of Scientific Advisory Board |
Che-Wei Hsu | 42 | 2022 | Independent Director |
Tsung-Shann Jiang | 70 | 2019 | Chief Scientific Officer, Chief Strategy Officer & Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核